Following his related presentation at the EADV 2020 Virtual Congress, our Editor-in-Chief, Peter C Taylor (University of Oxford, Oxford, UK), took the time to speak with us more about the IL-23 pathway in seronegative spondyloarthropathies.
- What are the seronegative spondyloarthropathies? (0:06)
- What have we learnt in recent years, based on therapeutic advances in this area? (1:16)
- What does this tell us with respect to the pathobiology related to this range of targeted therapies? (2:53)
- IL-23 is the common link across the group of disorders. Knowing that the primary pathology in spondyloarthropathies seems to be tendon/bone specific, how can this relationship be explained? Are there any new insights? (3:50)
Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the EADV 2020 Virtual Congress.
Share this Video
Related Videos In Axial Spondyloarthritis
Marina Magrey, ACR 2020 – Ixekizumab Response in Nr-axSpA Based on HLA-B27 and Disease Duration: The COAST-X Study
It was a pleasure to speak with Marina Magrey (Case Western Reserve University School of Medicine/ MetroHeath Medical Center, Cleveland, OH, USA) about the recent post-hoc analysis from the COAST X study (NCT02757352). The analysis was designed to evaluate the efficacy of ixekizumab at week 16 in patients with non-radiographic axial spondyloarthritis (nr-axSpA) with or […]
Denis Poddubnyy, ACR 2020 – Secukinumab for AxSpA Spinal Pain: SKIPPAIN Study
It was an absolute pleasure to discuss the 24-week results from the SKIPPAIN study (NCT03136861) with Denis Poddubnyy (Charité-Universitätsmedizin Berlin, Berlin, Germany ). The study, which is a phase IIIb trial, evaluated the efficacy and safety of secukinumab in reducing spinal pain and disease activity following a step-up dosing approach. His presentation entitled ‘Secukinumab Provides Significant […]
Anna Moltó, ACR 2020: TICOSPA Trial in Axial Spondyloarthritis
It was a delight to discuss with Anna Moltó (Hospital Cochin, Paris, France) the results of the TICOSPA trial (NCT03043846) which was designed to evaluate the benefit of treat-to-target in patients with axial spondyloarthritis. The abstract entitled ‘Cluster-randomized Pragmatic Clinical Trial Evaluating the Potential Benefit of a Tight-control and Treat-to-target Strategy in Axial Spondyloarthritis: The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!